共 2 条
Commentary: A Historical Review of Centers for Disease Control and Prevention Antiviral Treatment and Postexposure Chemoprophylaxis Guidance for Human Infections With Novel Influenza A Viruses Associated With Severe Human Disease
被引:5
|作者:
Havers, Fiona P.
[1
]
Campbell, Angela P.
[1
]
Uyeki, Timothy M.
[1
]
Fry, Alicia M.
[1
]
机构:
[1] Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,Mailstop A-32, Atlanta, GA 30333 USA
关键词:
avian influenza;
neuraminidase inhibitors;
antiviral treatment;
RANDOMIZED CONTROLLED-TRIAL;
OSELTAMIVIR-RESISTANT;
2009;
PLACEBO-CONTROLLED TRIAL;
UNITED-STATES;
RISK-FACTORS;
H5N1;
INFECTION;
H7N9;
VIRUS;
DOSE OSELTAMIVIR;
H1N1;
PROPHYLAXIS;
D O I:
10.1093/infdis/jix065
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Human infections with novel influenza A viruses are of global public health concern, and antiviral medications have a potentially important role in treatment and prevention of human illness. Initial guidance was developed by the U.S. Centers for Disease Control and Prevention after the emergence of human infections with avian influenza A(H5N1) and has evolved over time, with identification of influenza A(H7N9) virus infections in humans, as well as detection of avian influenza viruses in birds in the United States. This commentary describes the historical context and current guidance for the use of influenza antiviral medications for treatment and post-exposure chemoprophylaxis of human infections with novel influenza A viruses associated with severe human illness, or with the potential to cause severe human disease, and provides the scientific rationale behind current recommendations.
引用
收藏
页码:S575 / S580
页数:6
相关论文